Glioblastoma (GBM) Treatment in Shanghai: A Guide for International Patients
A diagnosis of glioblastoma multiforme (GBM) — the most aggressive primary brain tumor in adults — is one of the most difficult moments any patient and family can face. GBM is a Grade IV astrocytoma characterized by rapid growth, infiltration of surrounding brain tissue, and a high rate of recurrence even after aggressive treatment. Median survival with standard-of-care therapy is approximately 14–16 months, though outcomes vary significantly based on molecular markers, extent of surgical resection, and access to specialized multidisciplinary care.
For international patients, Shanghai offers a compelling combination: world-class neurosurgical expertise, access to advanced radiation technology, availability of temozolomide-based chemotherapy and tumor treating fields (TTFields), and an emerging clinical trial landscape for novel GBM therapies. This guide explains what to expect, which institutions and specialists to consider, and how China Medical Concierge Shanghai (CMCS) can coordinate your care from the first inquiry through treatment and follow-up.
Understanding GBM: Key Facts for Patients
Before choosing a treatment center, it helps to understand the biological and clinical features that drive GBM treatment decisions:
MGMT Promoter Methylation: Patients whose tumors have a methylated MGMT promoter respond significantly better to temozolomide (TMZ) chemotherapy. This is one of the most important biomarkers to establish at diagnosis. If your pathology report does not include MGMT methylation status, re-testing in Shanghai is recommended before finalizing a treatment plan.
IDH Mutation Status: IDH-mutant gliomas (more common in younger patients and lower-grade tumors that have transformed) carry a better prognosis than IDH-wildtype GBM. The 2021 WHO Classification of CNS Tumors now defines GBM as IDH-wildtype Grade IV — a distinction that affects both prognosis and treatment eligibility for certain clinical trials.
EGFR Amplification & EGFRvIII: Present in approximately 40–50% of GBMs, these alterations are targets of ongoing clinical research. Several trials in China are evaluating EGFRvIII-targeted therapies and CAR-T approaches for GBM.
TERT Promoter Mutation & Chromosome 10q/7p: Additional molecular features that refine prognosis and are increasingly incorporated into treatment planning at leading centers.
Standard Treatment Protocol for GBM
The Stupp Protocol remains the global standard of care for newly diagnosed GBM in eligible patients:
- Maximal safe surgical resection — the goal is gross total resection (GTR) while preserving neurological function. Intraoperative MRI, fluorescence-guided surgery (5-ALA), and awake craniotomy for eloquent area tumors are available at leading Shanghai centers.
- Concurrent radiotherapy + temozolomide (TMZ) — 60 Gy in 30 fractions over 6 weeks, with daily oral TMZ.
- Adjuvant TMZ chemotherapy — 6 cycles of TMZ (5 days on, 23 days off).
- Tumor Treating Fields (TTFields / Optune) — a wearable device delivering low-intensity alternating electric fields, shown to extend survival when added to adjuvant TMZ. Availability in China has expanded significantly in recent years.
At recurrence, treatment options include re-resection (if feasible), bevacizumab (Avastin), lomustine (CCNU), re-irradiation, and enrollment in clinical trials. Shanghai's leading centers have access to all of these modalities.
Leading Hospitals for GBM Treatment in Shanghai
Huashan Hospital (华山医院) — Fudan University
Huashan Hospital's Department of Neurosurgery is consistently ranked No. 1 in China and is the undisputed national leader for brain tumor surgery. The department performs more than 10,000 neurosurgical procedures annually and has dedicated neuro-oncology expertise that few institutions in Asia can match.
For GBM patients, Huashan offers:
- Intraoperative MRI-guided resection for maximal safe tumor removal
- 5-ALA fluorescence-guided surgery to identify tumor margins
- Awake craniotomy with cortical mapping for tumors in eloquent areas (speech, motor)
- Multidisciplinary neuro-oncology tumor board
- Access to clinical trials for recurrent and newly diagnosed GBM
- Integrated radiation oncology with stereotactic radiosurgery (SRS) capability
CMCS works with leading neurosurgeons at Huashan Hospital, including Prof. Zhou Liangfu (周良辅) — one of China's most celebrated neurosurgeons and a pioneer in the field — and Prof. Zhu Wei (朱巍), who specializes in complex skull base and intraventricular tumors.
Renji Hospital (仁济医院) — Shanghai Jiao Tong University
Renji Hospital's neurosurgery department has developed particular expertise in functional neurosurgery and glioma surgery in eloquent brain regions. For GBM patients whose tumors involve or are adjacent to areas controlling speech, movement, or vision, Renji's awake surgery program and intraoperative neurophysiological monitoring capabilities are highly relevant.
CMCS works with Dr. Zhou Liang (周亮) at Renji Hospital, whose expertise in functional area glioma surgery makes him a key referral for cases where tumor location presents particular surgical complexity.
Other Notable Centers
Zhongshan Hospital (中山医院) and Shanghai Changzheng Hospital (长征医院) also maintain active neurosurgery programs with GBM experience. For patients requiring integrated neuro-oncology management — particularly those seeking clinical trial access or novel systemic therapies — coordination across surgical and medical oncology teams is essential, and CMCS can facilitate this.
The Role of Neuro-Oncology in GBM Care
Surgery alone does not treat GBM — it is the first step in a prolonged multidisciplinary treatment journey. After resection, patients require:
- A radiation oncologist experienced in CNS tumors to plan and deliver concurrent chemoradiation
- A neuro-oncologist or medical oncologist to manage TMZ chemotherapy, monitor for toxicity, and evaluate response
- Ongoing MRI surveillance to distinguish true progression from pseudoprogression (a common challenge in GBM management)
- Supportive care including corticosteroid management, anti-epileptic therapy, and rehabilitation
CMCS coordinates across all of these specialties, ensuring that international patients have a coherent, integrated treatment plan rather than fragmented consultations across multiple departments.
Clinical Trials for GBM in Shanghai
Shanghai is one of China's most active centers for GBM clinical research. Ongoing and recently completed trials at leading Shanghai institutions have included:
- EGFRvIII-targeted CAR-T cell therapy for recurrent GBM
- PD-1/PD-L1 checkpoint inhibitors in combination with bevacizumab
- Novel alkylating agents and PARP inhibitors
- Oncolytic virus therapy
- Tumor treating fields (TTFields) combination studies
For patients with recurrent GBM who have exhausted standard options, clinical trial eligibility assessment is an important part of the consultation process. CMCS can help identify which trials are currently enrolling and whether a patient's molecular profile makes them a candidate.
What to Prepare Before Coming to Shanghai
To enable the most productive initial consultation, patients should gather the following before traveling or initiating a remote case review:
- MRI brain with and without contrast (most recent, ideally within 4–6 weeks) — digital files in DICOM format preferred
- Pathology report including histological diagnosis, WHO grade, and molecular markers (MGMT, IDH, EGFR, TERT, 1p/19q if tested)
- Operative report from prior surgery (if applicable)
- Radiation treatment summary (if applicable) including total dose, fractionation, and fields
- Chemotherapy records including agents, cycles completed, and response assessment
- Current medications including corticosteroids and anti-epileptics
- Neurological status summary — current functional status, any deficits, seizure history
CMCS provides medical record translation for documents in English, Arabic, French, Russian, and other languages. Remote pre-consultation review by the treating team is available before any travel commitment is made.
How CMCS Coordinates GBM Care in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For GBM patients, our coordination typically includes:
- Initial case review and triage to the most appropriate neurosurgeon and neuro-oncology team based on tumor location, molecular profile, and treatment history
- Medical record translation and preparation of a clinical summary for the treating team
- Appointment scheduling with neurosurgery, radiation oncology, and medical oncology
- On-site interpretation during all consultations, procedures, and family meetings
- Coordination of pre-operative workup, surgical scheduling, and post-operative care
- Clinical trial eligibility assessment and enrollment support
- Post-treatment follow-up coordination and MRI surveillance scheduling
- Liaison with the patient's home oncologist for continuity of care
Contact CMCS to Begin Your GBM Consultation
If you or a family member has been diagnosed with glioblastoma and are considering treatment in Shanghai, we encourage you to reach out as early as possible. Early consultation allows for the most treatment options and the best opportunity to participate in clinical trials if appropriate.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.
댓글 0개